Pharmaceutical companies just raised list prices for over 500 medicines, including Novo Nordisk’s Ozempic, Gilead’s HIV-1 ...

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

TCW Funds, an investment management company, released its “TCW Relative Value Large Cap Fund” Q3 2024 investor letter. A copy ...

The list prices of the top 25 drugs with the highest Medicare Part D spend that are not subject to drug price negotiations ...

Gilead Sciences will no longer provide four HIV ... impede nationwide efforts to combat the infectious disease. The list includes Truvada, a widely prescribed medicine that is used to treat ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like ...

As I noted in my last post, however: The drugs were so successful ... European Pharmas), and in 2023, Gilead's $27bn of revenues earned puts its 12th on the list. Its historic price to sales ...

And Gilead appears to be reaping the benefits ... Agencies sometimes choose not to list drugs because they cost more than existing treatments that perform equally well or because incremental ...

Livdelzi will launch at a list price of $12,606 for a 30-day treatment ... Seigerman predicted peak sales of $847 million for Gilead's drug. Both the PPAR drugs compete with Intercept Pharma's ...

Gilead Sciences, Inc. (NASDAQ:GILD) had two big announcements during the quarter: 1) the FDA approved its new liver disease treatment for biliary cholangitis and 2) its phase III HIV drug trial ...